Hisun Pharma Adjusts Product Distribution, Moves Forward
This article was originally published in PharmAsia News
Hisun Pharmaceutical has experienced ups and downs in recent years, but continuous adjustment of its product distribution has created brighter prospects and favorable ratings from investment analysts
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.